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Resumo 
O glaucoma é uma doença neurodegenerativa e uma das principais causas de cegueira 
em todo o mundo. O aumento da pressão intraocular é considerado um dos principais 
factores de risco para o desenvolvimento da doença. Contudo, mesmo pacientes com a 
pressão intraocular controlada continuam a perder a visão. Deste modo, é imperativo a 
existência de tratamentos mais eficazes e, a neuroprotecção das células ganglionares da 
retina mostra ser uma alternativa com potencial terapêutico. As células da microglia 
desempenham um papel importante no desenvolvimento do glaucoma, uma vez que, 
quando estas células ficam reactivas libertam mediadores inflamatórios que contribuem 
para o processo neurodegenerativo. 
A adenosina é um neuromodulador do sistema nervoso central e é um dos sistemas de 
neuroprotecção mais promissores no CNS. A modulação do recetor de adenosina A2A 
(A2AR) tem sido um assunto intensamente abordado na literatura como um potencial 
alvo terapêutico, visto que o bloqueio do A2AR confere neuroproteção, após dano no 
sistema nervoso central. 
A cafeína é o psicoestimulante mais usado em todo o mundo e os seus efeitos são 
maioritariamente mediados pelo bloqueio dos recetores de adenosina. Vários estudos 
mostram que o consumo de cafeína confere neuroproteção, após dano no sistema 
nervoso central.  
Os principais objetivos deste trabalho foram a) investigar se a modulação da atividade 
do A2AR controla a neuroinflamação na retina num modelo de isquémia-reperfusão (I-R); 
e b) investigar os efeitos anti-inflamatórios e neuroprotectores da cafeina no modelo de I-
R.  
Para tal foram usados dois grupos distintos de animais. O primeiro grupo de ratos 
Wistar foi previamente tratado através de injeção intravítrea de CGS 21680 (agonista do 
A2AR) ou SCH 58261 (antagonista do A2AR), 2 horas antes da indução de I-R na retina. Ao 
segundo grupo de ratos Wistar foi administrado cafeína na água, duas semanas antes da 
indução de I-R. Com isto, avaliou-se a reatividade das células da microglia, a produção de 
citocinas pro-inflamatórias e de espécies reativas de oxigénio.  
A injeção intravítrea do agonista ou antagonista do A2AR não alterou os níveis de TNF, 
IL-1β e de IL-6, no entanto, o antagonista diminuiu o número de microglias/macrófagos 
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reativas induzidas pela I-R da retina. Após 24 h de isquémia, a cafeína aumentou a 
reatividade das células da microglia, induzida pela I-R e aumentou a morte celular na 
retina. Por outro lado, após 7 dias de isquémia, a cafeína diminuiu a reatividade da 
microglia e a produção de citocinas e de espécies reativas de oxigénio. A cafeína também 
atenuou a morte das células ganglionares da retina, induzida por I-R. 
Em suma, os nossos resultados mostraram que a ativação ou o bloqueio do A2AR e o 
consumo de cafeína foi capaz de controlar a neuroinflamação, controlando a reatividade 
das células da microglia, conferindo neuroprotecção às células da retina.  
 
Palavras-chave: Glaucoma, neuroinflamação, recetores A2A de adenosina, cafeína, 
neuroproteção 
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Abstract 
Glaucoma is a retinal neurodegenerative disease and one of the main causes of 
blindness in the world. The increase in intraocular pressure (IOP) is considered the main 
risk factor for the development of glaucoma, but patients continue to lose vision despite 
adequate IOP control. Therefore, new and more effective treatments are necessary, and 
neuroprotection of retinal ganglion cells (RGCs) is considered a potential alternative 
therapy. Neuroinflammation plays an important role in the development of glaucoma. 
Microglia becomes reactive, leading to increased production of inflammatory mediators 
that contribute for the neurodegenerative process. 
Adenosine is a neuromodulator in the central nervous system (CNS). It has been 
claimed that adenosine is one of the most promising neuroprotective systems in CNS. 
Much attention is being given to adenosine A2A receptor (A2AR) modulation as potential 
therapeutic target since the blockade of A2AR affords robust neuroprotection upon CNS 
injury.  
Caffeine is the most commonly used psychostimulant in the world and its effects are 
mainly mediated by antagonizing adenosine receptors. Many studies show that caffeine 
consumption affords neuroprotection upon CNS injury.  
The main goals of this work were a) To investigate whether the modulation of A2AR 
activity controls retinal neuroinflammation in ischemia-reperfusion (I-R) model; and b) To 
investigate the anti-inflammatory and neuroprotective effects of caffeine in I-R model. 
Two groups of animals were used. The first group of Wistar rats was pretreated either 
with CGS 21680 (A2AR agonist) or SCH 58261 (A2AR antagonist) by intravitreal injection, 2 
hours prior to I-R injury. The second group of Wistar rats received with caffeine (1 g/L) in 
drinking water, 2 weeks prior to injury. Microglia reactivity, levels of pro-inflammatory 
cytokines, ROS generation, and cell death and RGC loss were assessed. 
Intravitreal injection of A2AR agonist or antagonist did not change the levels of TNF, IL-
1β and IL-6. However, A2AR antagonist decreased the number of reactive 
microglia/macrophages induced by I-R injury. After 24h post-ischemia, caffeine 
exacerbated the reactivity of microglia induced by I-R injury, and increased cell death. On 
the other hand, 7 days post-ischemia, the treatment with caffeine decreased microglia 
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reactivity, and the production of cytokines and reactive oxygen species (ROS). Caffeine 
was also able to attenuate RGC death, induced by I-R injury. 
In summary, our results demonstrated that the activation or blockage of A2AR and the 
caffeine consumption was able to control the neuroinflammatory response by microglia, 
controlling their reactivity and affording neuroprotection to retinal cells.  
 
Keywords: Glaucoma, neuroinflammation, adenosine A2A receptors, caffeine, 
neuroprotection 
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1. Introduction  
 
1.1. Vision  
“The eyes are our door to the world”.  Our perception of the world in terms of its 
colors and its shapes is given to us by the eyes. This is a highly specialized organ of 
photoreception, in which light energy from the environment produces changes in 
specialized nerve cells in retina, thereby forming nerve action potentials which are 
transmitted through optic nerve to the brain, where the information is processed.  
 
1.2. Anatomy of eyeball 
The eye is divided into three layers (Figure 1). The outermost layer of the eye is 
composed by the sclera, a conjunctive tissue layer that helps maintaining the eye shape and 
protects the internal structures. This opaque layer is contiguous to the cornea, in the 
anterior part of the eye, a specialized transparent tissue that allows light rays to enter the 
eye.  
 
 
 
Figure 1 - Anatomy of human eyeball (adapted from http://www.sciencephoto.com/). 
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The immediately adjacent layer is the uveal tract which includes three distinct 
structures: iris, ciliary body and choroid. The iris is the colored portion of the eye and can 
be seen through the cornea. It contains two sets of muscles with opposite actions that 
can increase or decrease the pupil’s diameter to admit more or less light entering. The 
ciliary body is a muscular component and it is attached to the lens by zonule fibers whose 
function is to determine the refractive power of lens, allowing image formation. The 
ciliary body has a vascular component which produces the aqueous humor that fills the 
anterior and posterior chambers of the eye (Figure 1). Aqueous humor is secreted in the 
posterior chamber and passes through the pupil into the anterior chamber. Choroid is rich 
in blood vessels and its main function is to nourish the outermost layers of the retina. The 
retina is the most inner layer of the eye and it is a light sensitive tissue that has the 
function of photoreception and transmits impulses to the brain. The portion of the eye 
located between the lens and the surface of retina is the vitreous chamber and it is filled 
by a viscous substance called vitreous humor (Purves et al., 2001).  
 
1.3. Retina 
Retina is part of the central nervous system (CNS) and it is constituted by three main 
types of cells: neurons, glial cells and blood vessels  (Kolb et al., 1995). 
 
1.3.1. Neurons 
The neuronal component of the retina is composed by five different types of neuronal 
cells: photoreceptors (rods and cones), bipolar cells, horizontal cells, amacrine cells and 
retinal ganglion cells (RGCs) (Figure 2).  
The retinal pigment epithelium (RPE) is the outermost layer of retina and is composed 
by a single layer of hexagonal cells. Interactions between retinal pigmented cells and 
photoreceptors are essential for visual function (Kolb et al., 1995). Neuronal cells bodies 
are divided into three different layers: the outer nuclear layer (ONL) that contains the cell 
bodies of rods and cones, the inner nuclear layer (INL) that contains the cell bodies of 
bipolar, horizontal and amacrine cells, and the ganglion cell layer (GCL) that contains cell 
bodies of ganglion cells and displaced amacrine cells. The axons of ganglion cells travel 
towards the optic nerve within the nerve fiber layer (NFL).  Moreover, there are two 
Introduction 
 
3 
layers of synapses: the outer plexiform layer (OPL), where photoreceptors make synapses 
with bipolar and horizontal cells, and the inner plexiform layer (IPL) that connects bipolar 
cells to RGCs (Kolb et al., 1995). 
When light reaches the retina it passes across these layers and photoreceptors traduce 
this light into electrical signals. In the vertical signal pathway, photoreceptors transmit 
signals to bipolar cells which make synaptic contact with ganglion cells. The horizontal 
pathway, provided by horizontal cells, enables interactions between photoreceptors and 
bipolar cells at OPL, and amacrine cells, which affect bipolar and ganglion cells 
interactions (Cervia and Casini, 2012). 
 
1.3.1.1. Photoreceptors 
Photoreceptors consist of 1) an outer segment containing the visual pigment 
molecules (rhodopsin); 2) an inner segment that contains mitochondria, ribosomes and 
membranes where opsin molecules are assembled and passed to be part of the outer 
Figure 2 - Structural layers of the retina. Photoreceptors, bipolar cells and ganglion cells provide the 
most direct route for transmitting visual information to the brain. Horizontal and amacrine cells mediate 
lateral interactions in the outer and inner plexiform layers (adapted from Purves et al., 2001). 
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segment discs; 3) a cell body with nucleus of photoreceptor cell; 4) a synaptic terminal 
where neurotransmission with other neuronal cell types occurs. 
In the retina there are two types of photoreceptors: rods and cones. Cones are robust 
conical-shaped structures with their outer/inner segments protruding the RPE. In 
darkness there is a high release of glutamate by cones. Rods are slim rod-shaped 
structure filling the space between cones (Kolb et al., 1995). 
 
1.3.1.2. Bipolar cells  
Bipolar cells receive neurotransmission signals from photoreceptors and transmit them 
to amacrine and ganglion cells. In the human retina, ten different bipolar cells are present 
to receive signals from cones and one type to receive inputs from rods (Kolb et al., 1995). 
The postsynaptic neurons in OPL express different glutamate receptors which allow 
the distribution of signal into multiple pathways, based on how cone bipolar cells react to 
glutamate released by cones. Horizontal and OFF cone bipolar cells express ionotropic 
glutamate receptors and are hyperpolarized by light. ON cone bipolar cells express 
metabotropic glutamate receptors and are depolarized by light (Kolb et al., 1995). 
 
1.3.1.3. Ganglion cells 
Ganglion cells collect signals from bipolar and amacrine cells and transmit them 
through axons to the brain. Ganglion cells are also divided into OFF and ON and have a 
different response, according to pathways initiated by bipolar cells (Kolb et al., 1995). 
 
1.3.1.4. Horizontal cells 
Horizontal cells are the interneurons in the retina and the second neurons that contact 
directly with photoreceptors. These cells provide negative signals to cones contributing to 
the maintenance of visual sensitivity to light (Kolb et al., 1995). 
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1.3.1.5. Amacrine cells  
Amacrine cells are interneurons that interact with bipolar cells and RGCs at the level of 
IPL, and different kinds of amacrine cells can be found in the retina. These are inhibitory 
interneurons which contribute to visual function (Kolb et al., 1995). 
 
1.3.2. Blood vessels    
The retinal tissue has higher levels of oxygen consumption per unit of tissue weight 
than any other human tissue. For this reason, the retina needs an efficient supply of 
oxygen and nutrients (Klaassen et al., 2013). There are two distinct vascular beds that 
provide blood supply to the retina, the choroidal blood vessels and the central retinal 
artery (Kolb et al., 1995; Pournaras et al., 2008). The first one provides blood supply to 
photoreceptors in the outer retina, while the central retinal artery gives rise to capillaries 
that innervate the inner retina (Klaassen et al., 2013).  
Cellular barriers are required to maintain an appropriate, tightly regulated 
environment around cells. Endothelial cells which constitute the blood-retinal barrier 
(BRB) play a critical role in restricting the nonspecific transport of hydrophilic substances 
and facilitating the transport of essential molecules between the circulating blood and the 
retina (Fernandes et al., 2011).  
The BRB is divided into two components (Figure 3), the inner blood-retinal barrier 
(iBRB) and the outer blood-retinal barrier (oBRB) (Pournaras et al., 2008). The iBRB is 
constituted by the endothelium, that composes intraretinal blood vessels; pericytes which 
are modified smooth muscle cells of capillaries and may have contractile functions that 
regulate retinal vascular flow by dilating and contracting (Gardner et al., 2002; Pournaras 
et al., 2008); and glial cells, which provide signals that have impact on the development 
and maintenance of the barrier (Pournaras et al., 2008). The oBRB is composed by the 
endothelium of the choriocapillaris, Bruch’s membrane and RPE (Pournaras et al., 2008).  
Several mechanisms for BRB loss and leakage have been proposed and some diseases, 
such as diabetic retinopathy, age-related macular degeneration, retinal vein occlusion and 
uveitis may be associated with BRB breakdown (Klaassen et al., 2013).  
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1.3.3. Glial cells  
The third type of cells that compose the retina are glial cells. There are three types of 
glial cells in retina: Müller cells, astrocytes, and microglia, which have a role of neuro-
supporting and immunocompetent defense (Langmann, 2007).  
 
1.3.3.1. Müller cells 
Müller cells are the principal glial cells which span the entire depth of the retina and 
play an essential role in the normal function of the retina. The main function of Müller 
cells is the regulation of extracellular concentration of K+, which increases after light 
stimulation. Müller cells also play an important role in removing neurotransmitters, such 
as glutamate, from extracellular space following their release in the synaptic terminal 
(Newman and Reichenbach, 1996; Gardner et al., 2002).   
 
Figure 3 - Schematic diagram of the blood-retinal barrier. RPE: retinal pigment epithelium; POS: 
photoreceptor outer segments; OLM: outer limiting “membrane”; ONL: outer nuclear layer; OPL: outer 
plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer; NFL: nerve 
fiber layer; ILM: inner limiting “membrane” (Hosoya and Tomi, 2008). 
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1.3.3.2. Astrocytes 
Astrocytes are mostly located in NFL and they have several important physiological 
properties that are related to CNS homeostasis (Gardner et al., 2002). In response to 
stimuli, astrocytes proliferate, change their morphology and increase the expression of 
glial fribrillary acidic protein (GFAP), a process designated as astrogliosis (Hasko et al., 
2005). 
Moreover, astrocytes are part of the BBR, having a close association with retinal 
vessels and regulating its properties. In addition, due to their abundant contents in 
glycogen, they form a nutritive support in providing glucose to neurons (Kolb et al., 1995). 
 
1.3.3.3. Microglia 
Microglia cells are the resident macrophages of the CNS and their function is the 
surveillance of the microenvironment. At this stage, microglia has a ramified morphology 
in which long thin processes extend from the cell body (Kettenmann et al., 2011; 
Morrison and Filosa, 2013).  
When CNS homeostasis is impaired by several factors, such as infection, trauma, 
ischemia and neurodegenerative disease, microglia adopts a so-called activated state with 
a globular phagocyte structure (Hasko et al., 2005; Bosco et al., 2011). Despite this 
morphological transition being clearly described, the different stages of microglial 
activation are not well understood. A recent study has focused on this issue, proposing 
that there are six stages of bidirectional microglial activation and deactivation (Jonas et 
al., 2012). 
Upon inflammation and infection, exogenous signals can lead to more microglial 
activation through the recognition of pro-inflammatory mediators by surface molecules of 
microglia (cytokines receptors, scavenger receptors, pattern recognition receptors and 
chemokines receptors). Activation of these receptors leads to a microglial phenotype 
transition into an activated state, which contributes to the ongoing inflammation process 
(Kierdorf and Prinz, 2013). However, chronic microglial activation leads to neuronal 
death, which is closely related with neurodegenerative diseases progression such as 
Alzheimer’s disease, Parkinson’s disease, and also glaucoma. More attention has been 
given to interactions between neurons and glia as being the cause underlying the 
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degenerative process in these diseases. As recently reviewed, neurotransmitters, such as 
glutamate, gamma-aminobutyric acid (GABA), adenosine 5’-triphosphate (ATP), 
catecholamines (adrenaline, noradrenaline and dopamine) and acetylcholine, may 
modulate microglial-mediated neuroinflammation, since microglia express most of the 
receptors for those transmitters. ATP is released at high concentrations upon cell death 
and tissue destruction and later, it is rapidly degraded to adenosine 5’-diphosphate (ADP) 
and adenosine which then play their physiology functions by activating specific receptors 
(Lee, 2013). 
 
1.3.3.4. Retinal microglial cells 
There is a lot of research data that focuses in microglia homeostasis in CNS, but less is 
known about the function of microglial cells of the retina.  
In the retina, microglial cells soma are located at the NFL, GCL as well as within IPL or 
above the INL (Bosco et al., 2011).  
When microglial cells become active, their neurosupportive functions are 
compromised, leading to increased vulnerability of RGCs and driving their axons to injury 
(Tezel, 2011). The localization of microglia in the GCL and IPL suggests that microglia can 
signal to RGCs, and in case of exacerbated microglial activation, promote cell death. 
In different retinal regions, microglia cells are responsible for the surveillance of the 
environment with their highly motile protrusions (Figure 4A). Various stimuli lead to 
degeneration alert microglia (Figure 4B), which migrate to the lesion site and turn into 
their active state (Figure 4C) (Karlstetter et al., 2010).  
Introduction 
 
9 
 
1.4. Glaucoma  
Glaucoma is one leading cause of blindness in the world. Globally, it was estimated 
that 60 million people have glaucomatous optic neuropathy, and an estimated 8.4 million 
people are blind as a result of glaucoma (Cook and Foster, 2012). 
In the past, glaucoma was defined by an elevation of intraocular pressure (IOP). Today, 
glaucoma is considered a neurodegenerative disease, characterized by degeneration of 
the optic nerve and loss of RGCs (Vohra et al., 2013). 
Elevated IOP and age are the most recognized risk factors and the current therapies 
available are focused in reducing IOP (Johnson and Morrison, 2009). Nevertheless, even 
patients with normal IOP can be affected by this neuropathy. 
Currently, the exact mechanism that initiates and leads to a glaucomatous optic nerve 
degeneration and RGCs loss is not fully understood. Many studies propose several 
Figure 4 - Schematic representation of three common phases of microglial activity in the retina: A) in 
normal retina, B) various different insults leading to abnormal cell functions or degeneration in the RPE, 
the photoreceptor layer, and the ganglion cell layer rapidly alert microglia, C) microglial transformation 
into amoeboid morphology leading to an inflammatory response (RPE: retinal pigment epithelium; ONL: 
outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: 
ganglion cell layer) (Karlstetter et al., 2010). 
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mechanisms which play an important role in glaucomatous neurodegeneration. Oxidative 
stress, due to mitochondrial dysfunction is one of many mechanism proposed (Tezel, 
2011). Another proposed mechanism for glaucoma development is related with vascular 
deregulation (Leske, 2009).  
Microenvironment signals, which are triggered by macroglial and microglia cells, are 
suggested to be important enhancers of glaucomatous neurodegeneration (Johnson and 
Morrison, 2009; Tezel, 2011).   
 
1.4.1. Glaucoma and neuroinflammation 
During the last years, microglia has been linked to the development of 
neurodegenerative disorders in which neuroinflammation is an integral part, in an initial 
phase of disease development and microglia initiates repair mechanisms. However, an 
exaggerated microglial reaction may lead to chronic inflammation (Langmann, 2007; 
Karlstetter et al., 2010).    
In an animal model of glaucoma, the DBA/2J mouse, with ocular hypertension, much 
effort has been made better to understand the role of glia. Microglial changes occur 
earlier than RGCs pathology, and no correlation between IOP elevation and microglial 
activation was found, indicating that IOP elevation may not be a contributing factor in the 
initial changes of this disease development (Bosco et al., 2011). In contrast, Son et al. 
mentioned that activation of microglia is a process that occurs after large-scale neuronal 
loss in DBA/2J animal model of chronic glaucoma (Son et al., 2010).  
Likewise, in human glaucoma, abnormal activated ameboid cells were found (Neufeld 
and Liu, 2003). Regarding pro-inflammatory cytokines, it is described that there is an 
increase in their levels in the retina of glaucoma patients (Tezel et al., 2001). Moreover, 
aqueous humor analysis of glaucoma patients demonstrate increased levels of pro-
inflammatory cytokines (Kuchtey et al., 2010; Sawada et al., 2010; Chua et al., 2012).  
It is commonly accepted that glial activation and the prominent stimulation of pro-
inflammatory signalling are a hallmark of neuroinflammation in the CNS which, in the 
presence of accumulating risk factors, can result in dysfunction of regulatory mechanisms.  
 
Introduction 
 
11 
1.4.2. Ischemia-Reperfusion Model 
In several eye diseases, like in glaucoma, retinal ischemia is a clinical entity involved in 
the disease development and is a common cause of visual impairment and blindness. 
Despite this, the role of retinal ischemia in these diseases is not well understood (Cervia 
and Casini, 2012; Chen et al., 2013). 
Ischemia may be defined as an inefficient blood supply to the tissue, resulting in 
hypoxia and failure of tissue nutrient demands (Osborne et al., 2004). 
In clinical diseases, like glaucoma, it is very difficult to study pathophysiology in human 
patients. For this reason, the development of animal models of glaucoma is extremely 
important, in order to understand the underlying mechanism of disease and to develop 
new therapies. A wide variety of rodent models for glaucoma exist and ischemia-
reperfusion (I-R) model is one of the examples. This I-R model is characterized by an 
elevation of IOP above systolic pressure and allows us to control the magnitude and 
duration of ischemia, as well as the duration of reperfusion, which are very important 
parameters concerning RGCs death (Selles-Navarro et al., 1996; Johnson and Tomarev, 
2010).  
Although it does not directly follow the exact pathophysiology that occurs in human 
glaucoma, it is important to induce a specific insult to RGCs (Johnson and Tomarev, 2010). 
 
1.5. Adenosine 
Adenosine is a purine nucleoside present in all tissues and body fluids that behave as a 
general modulator of biological functions, such as energy metabolism. Under basal 
conditions, adenosine concentration is kept constant at low levels (20-200 nM) but under 
metabolic stress or under pathophysiological conditions there is an increase of adenosine 
levels to 10 µM (Schulte and Fredholm, 2003; Cunha et al., 2007). Also in the retina, 
adenosine concentration increased after 5 min of ischemia and even during reperfusion 
period (Li and Roth, 1999).   
The first report of adenosine’s physiological effects was described in cardiovascular 
system, in 1929, but adenosine also plays an important role in the immune system, cell 
growth, proliferation, apoptosis and in the central nervous systems (Schulte and 
Introduction 
 
12 
Fredholm, 2003). Also, in retina, adenosine plays an important role in many physiological 
mechanisms such as in the regulation of the IOP (Wan et al., 2011).  
Adenosine is produced intracellularly as well as extracellularly (Figure 5). Intracellular 
adenosine production is either by breakdown of adenosine 5’-phosphates (AMP, ADP, 
ATP) which is mediated by an intracellular 5’-nucleotidase or by hydrolysis of S-adenosyl-
homocysteine (SAH). The extracellular adenosine can be originated from intracellular pool 
through nucleoside transporters present in membrane or by fast nucleotide hydrolysis 
catalyzed by a cascade of ectoenzymes (ecto-ATPase, ecto-ATP-diphosphohydrolase and 
ecto-5’ nucleotidase). Adenosine can be metabolized by phosphorylation to AMP or 
degradated to inosine, which is then catalyzed by adenosine kinase and adenosine 
deaminase, respectively (Schulte and Fredholm, 2003; Hasko et al., 2005; Haskó et al., 
2008). 
Once present extracellularly, adenosine effects are mediated by four distinct 
membrane adenosine receptors. All of the adenosine receptors are metabotropic and are 
composed of seven transmembranar domains with the N-terminus at the extracellular 
and the C-terminus at the intracellular face of the membrane; and are coupled to 
intracellular GTP-binding proteins (G proteins). These receptors are called pleiotropic 
receptors because different types of receptors are coupled to different G proteins with 
Figure 5 - Mechanism underlying formation of extracellular adenosine (Sachdeva and Gupta, 2012). 
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different transducing systems according to the degree of activation and localization of the 
receptors (Cunha, 2005). So the effect of adenosine is mediated by four adenosine 
receptors (ARs) – A1 receptor (A1R), A2A receptor (A2AR), A2B receptor (A2BR) and A3 
receptor (A3R). A1R and A3R are coupled to an inhibitory G protein (Gi) whereas A2AR 
and A2BR are coupled to a stimulatory G protein (Gs), inhibiting or stimulating adenylyl 
cyclase (AC) activity, respectively (Jacobson and Gao, 2006).  
 
1.5.1. A1 receptors  
 The A1R is coupled with Gi, and when this receptor is activated, AC activity is inhibited 
with no increase in levels of cyclic adenosine 5’-monophosphate (cAMP) (Jacobson and 
Gao, 2006). Additionally, this receptor is linked to various kinase pathways including 
protein kinase C (PKC), phosphoinositide 3 (PI3) and mitogen-activated protein (MAP). 
A1R activation can, also, activate K+ channels and inhibit Ca2+ channels (Figure 6) (Hasko 
et al., 2008). 
Figure 6 - Schematic diagram depicting the downstream signaling pathways of adenosine 
receptors  (Adapted from (Dias et al., 2013). 
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A1R are the most abundant and widespread adenosine receptors in the brain. This 
receptor is most abundant in limbic and neocortical regions, and is mostly concentrated 
in neurons, especially in synapses (Cunha, 2005; Cunha et al., 2007). A1R are also present 
in astrocytes and microglia although in less number (Cunha, 2005). 
When A1R are activated in presynaptic neurons, the release of excitatory 
neurotransmitters is inhibited and when they are activated in postsynaptic neurons, the 
excitatory action potential is inhibited. This action has a profound impact on synaptic 
transmission, controlling the release of glutamate, acethylcoline and serotonin, causing a 
depressant, sedative and anticonvulsant effect (Abbracchio and Cattabeni, 1999; Cunha, 
2005). 
The agonists of this receptor have been used as a therapy for cerebral ischemia and 
brain trauma. However, the administration of A1R has collateral effects such as profound 
sedation and hypotension (Abbracchio and Cattabeni, 1999). 
The improvement of the neuroprotective effect of A1R resides in the development of 
partial agonists for these receptors, reducing the extent of desensitization and in the 
identification of A1R subtypes that can lead to better pharmacology manipulation. 
Another process that can improve neuroprotective effects of A1R is the development of 
Regulators of Endogenous Adenosine Levels (REAL) agents which influence adenosine 
transport, metabolism and/or release, decreasing adenosine levels after trauma or 
ischemia (Abbracchio and Cattabeni, 1999). 
  
1.5.2. A2A receptors  
A2AR is coupled to Gs protein, and its activation leads to an increase of cAMP levels 
due to increased AC activity. These high levels of cAMP lead to activation of protein 
kinase A (PKA) which proceeds through phosphorylation of the transcription factor of 
cAMP responsive element binding protein (CREB), resulting in its activation (Figure 6) 
(Hasko et al., 2008). 
A2AR were initially identified in striatum and are implicated in regulation of motor 
functions. These receptors are also present in the hippocampus and cortex, which are 
abundantly located in synapses. A2AR are also located in astrocytes and microglia cells, as 
well as in blood vessels. In striatum, A2AR are most abundant post-synaptically and in 
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other brain sites in presynaptic neurons (Cunha, 2005). A2AR can also be found in the 
retina, being highly expressed in retinal microglial cells (Liou et al., 2008). 
An increase of expression and density of A2AR was reported as a result of Alzheimer’s, 
Parkinson’s and Huntington’s disease (Sebastiao and Ribeiro, 2009). Moreover, activated 
microglia cells also present an increased density of A2AR (Lee, 2013) suggesting that 
blockade of A2AR has a preponderant effect in latter stages of brain damage and in 
chronic noxious brain conditions (Cunha, 2005).  
Unlike to A1R, the prolonged administration of A2AR antagonists does not provoke 
desensitization, which makes this receptor an attractive target for modulation of brain 
injury. 
  
1.5.3. A2B receptors  
A2BR stimulation can trigger AC activation via Gs protein, which leads to cAMP 
formation and by activation of PKA also leads to CREB phosphorylation, resulting in its 
activation (Figure 6) (Schulte and Fredholm, 2003).  
A2BR are present in many cell types although in low abundance. Unlike A2AR, this 
receptor has low affinity for adenosine (Fredholm et al., 2001; Schulte and Fredholm, 
2003), thus A2BR activation requires pathophysiological conditions when adenosine levels 
are high and capable of their activation (Hasko et al., 2008).  
 
1.5.4. A3 receptors  
Similarly to A1R, activation of A3R is coupled to Gi, inhibiting AC activity and 
stimulating phospholipase C (PLC) (Figure 6) (Abbracchio and Cattabeni, 1999).  
A3R distribution in the brain is diffuse and can be detected in all brain areas although 
in a much lower density than the other subtypes of receptors (Abbracchio and Cattabeni, 
1999).  
These receptors are activated under specific conditions characterized by elevated local 
adenosine concentrations, since A3R have low affinity for adenosine  (Mendonca et al., 
2000).  
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1.6. Neuroprotective role of A2AR modulation 
Activated microglia cells secrete inflammatory mediators which can contribute to the 
resolution of the inflammatory process or to neuronal damage. Several results show that 
the blockade of A2AR provides neuroprotection controlling microglia reactivity which is 
an important target in several brain conditions (Cunha, 2005).  
 
1.6.1. A2AR agonist (CGS 21680) or antagonist (SCH 58261) 
Several pharmacological tools are used to study ARs. CGS 21680 is an A2AR-selective 
agonist but it is less potent and selective in humans than in rats. Moreover, in organs with 
levels of A2AR, CGS 21680 also binds to sites unrelated with A2AR. SCH 58261 is the most 
selective A2AR antagonist (Fredholm et al., 2001). It is controversial in the literature if 
activation or blockade of A2AR plays a protective role in CNS injuries. It is proposed that 
in CNS A2AR exerts a bidirectional effect (protective and deleterious) that depends on 
several factors: a) different development stages, b) different stages of pathological 
process after injury and c) different routes and times of A2AR drug administration (Dai 
and Zhou, 2011).  
Recently, it was shown that SCH 58261 has the ability to control neuroinflammation 
induced by lipopolysaccharide (LPS) which is a constituent of bacteria’s membrane and a 
potent activator of microglia. Interestingly, SCH58261 also attenuated LPS-induced 
increase in interleukin (IL)-1β levels and activated microglia recruitment (Rebola et al., 
2011). Moreover, some studies show that this selective A2AR antagonist ( SCH 58621) can 
prevent the hippocampal neuronal dysfunction and neurotoxicity triggered by the 
administration of LPS (Cunha, 2005). In addition, the administration of SCH 58261 
significantly reduced, in about 30%, the ischemic injury in the rat model of focal cerebral 
ischemia (Monopoli et al., 1998). 
 
1.6.2. Caffeine 
Caffeine (1,3,7–trimethylxanthine), which is present in coffee, tea, soft drinks, and 
chocolate, is the most commonly used psychostimulant in the world. This molecule has 
been subjected to extensive research with the objective to determine if it has impact on 
various biochemical and physiological processes. 
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In humans, after ingestion, 99% of caffeine is absorbed from the gastrointestinal tract 
in humans in about 45 min. Due to its hydrophobic properties caffeine is able to cross all 
biological membranes. Oral ingestion of a single cup of coffee in humans provides a 
caffeine dose of 0.4 to 2.5 mg/kg, leading to a peak serum concentration of 0.25 to 2 
mg/L or approximately 1 to 10 µM (Fredholm et al., 1999).  
Caffeine is almost completely metabolized in the liver and only 2% of the quantity 
ingested can be found in urine unaltered (Xu et al., 2010). For doses lower than 10 mg/kg, 
the half-life of caffeine varies from 0.7 to 1.2 h in rat and mouse and 2.5 to 4.5 h in 
humans (Fredholm et al., 1999). The first metabolic step of caffeine metabolism, which 
represents on average 80% of the total, is via N-3 demethylation to paraxanthine (1,7–
dimethylxanthine), primarily by the cytochrome P450 1A2 enzyme. Another two 
important metabolites are theobromine (3,7-dimethylxanthine) and theophylline (1,3-
dimethylxanthine) which represent about 16% of caffeine’s metabolism (Xu et al., 2010). 
In rodents, after caffeine administration, paraxanthine levels are high as well as levels of 
theophylline.   
In animal experiments, it was demonstrated that a treatment with caffeine (1g/L) 
supplied in drinking water confers prevents memory impairment (Duarte et al., 2009; 
Cognato et al., 2010), and also prevents neurodegeneration in a chronic Parkinson’s 
disease rat model (Sonsalla et al., 2012). Moreover, epidemiologic studies have shown 
that caffeine consumption is inversely correlated with the risk of developing 
neurodegenerative diseases, which are associated with chronic neuroinflammation 
(Prediger, 2010). Regarding inflammation, caffeine has also the ability to attenuate 
inflammation induced by LPS (Brothers et al., 2010b).  
It seems that prolonged administration of A2AR antagonists does not desensitize the 
receptor. In particular, long exposure of caffeine leads to a rapid A1R desensitization but 
maintains the A2AR mediated response (Cunha, 2005).  
Despite of extensive research about caffeine effects in CNS, little is known about its 
effects in the retina and its neuroprotective role in the I-R model. 
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Aims 
Glaucoma is a neurodegenerative disease characterized by damage in the optic nerve 
and loss of RGCs. Neuroinflammation is believed to contribute to the pathophysiology of 
glaucoma, increasing the reactivity of microglia and in the release of pro-inflammatory 
mediators. The blockade of A2AR confers robust neuroprotection in several brain noxious 
conditions, possibly through the control of neuroinflammation.  
The main aims of this project were to investigate whether the modulation of the 
adenosinergic system, in particular the role of A2AR, controls retinal pro-inflammatory 
responses and if it confers neuroprotection to the retina in a model of I-R. The role played 
by A2AR was assessed by injecting the A2AR agonist or antagonist in the vitreous.  
Caffeine is a non-selective antagonist of adenosine receptors and it has been reported 
that this substance prevents the neurodegenerative process in some diseases. Therefore, 
the effects of caffeine in the modulation of the retinal pro-inflammatory responses and in 
neuroprotection were also investigated.  
In order to accomplish our goals, we assessed the reactivity of microglia and the 
production of pro-inflammatory cytokines, as well as the production of reactive oxygen 
species (ROS). Cell death and loss of RGCs were also evaluated. 
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Figure 7 - Schematic representation of A2AR agonist (CGS 21680) or antagonist (SCH 58261) 
administration experimental procedure. 
2. Materials and Methods 
 
2.1. Animals and Drug administration 
Wistar rats aged 8 weeks were housed under controlled environment (21.8±0.1 C of 
temperature and, 67.6±1.6 % of relative humidity, 12 h-light/dark cycle) with free access 
to food and water. The animals were treated in agreement with the Association for 
Research in Vision and Ophthalmology (ARVO) statement for the use of animals in vision 
and ophthalmic research. 
 
2.1.1. Intravitreal administration of A2AR agonist or antagonist 
Animals were randomly divided for the treatment with saline, A2AR agonist or 
antagonist. The A2AR agonist CGS 21680 (Tocris Bioscience, Cambridge, UK) and the A2AR 
antagonist SCH 58261 (Tocris Bioscience, Cambridge, UK) were dissolved in dimethyl 
sulfoxide (DMSO) to a concentration of 100 mM, and then diluted and stored in Mili-Q 
water at 30 mM and 5 µM, respectively. Immediately prior to the intravitreal injection, 
CGS 21680 and SCH 58261 were diluted in sterile saline (0.9% NaCl, Labesfal) to a 
concentration of 2 mM and 100 nM, respectively. CGS 21680 dose was selected based on 
previous report  (Li and Roth, 1999). Intravitreal injection of CGS 21680 (1 µl + 4 µl saline) 
and SCH 58261 (5 µl) was performed using a 10 µL Hamilton syringe, in both eyes 2h 
before the induction of retinal ischemia-reperfusion (I-R), as indicated in Figure 7. 
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Figure 8 - Schematic representation of caffeine (1 g/L) administration experimental procedure. 
The animals were randomly divided into three experimental groups:  
i) Intravitreal injection of 5 µl of sterile saline (0.9% NaCl) followed by 
retinal I-R (saline); 
ii) Intravitreal injection of 5 µl of 2 mM CGS 21680 followed by retinal I-R 
(CGS 21680);
iii)  Intravitreal injection of 5 µl of 100 nM SCH 58261 followed by retinal I-R 
(SCH 58261). 
 
2.1.2. Caffeine administration 
Animals were randomly divided for the treatment with caffeine or water. Caffeine (1 
g/L, Sigma-Aldrich) was supplied in the drinking water for two weeks before performing 
retinal I-R and until the end of the experiment, as indicated in Figure 8. This dose of 
caffeine was selected based on previously reported ability to affords protection upon CNS 
injury (Xu et al., 2010). 
Caffeine solution was prepared fresh every two days.  
The animals were divided into three experimental groups:  
i) Retinal ischemia-reperfusion injury, drinking water (water); 
ii) Retinal ischemia-reperfusion injury, treatment with caffeine (caffeine); 
iii) Non ischemia-reperfusion injury, treatment with caffeine (non I-R caffeine).  
 
2.2.  Measurement of intraocular pressure  
The IOP was measured bilaterally 3 days a week with a rebound tonometer specifically 
designed for rodents (Tonolab®, Icare, Espoo, Finland), and was conducted between 1:00 
p.m. and 4:00 p.m. (Figure 9). Six reliable measurements were made by internal software 
which generates and displays an average, after elimination of high and low readings. For 
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the purpose of this study, this machine-generated average was considered as one 
reading. For each measurement, six machine-generated readings were recorded in each 
eye. An average of these readings was then calculated and was reported as the IOP for 
that eye. Basal IOP was measured one week before starting the treatment with caffeine.  
 
2.3. Retinal ischemia-reperfusion (I-R) injury  
Retinal I-R was induced in one eye by elevating the IOP to 80 mmHg for 60 min. 
Animals were anesthetized with 2.5% isoflurane (IsoFlo, Abbott Laboratories) in 1 L/min 
O2 with a vaporizer throughout the procedure of ischemia, and were placed on a heating 
plate to maintain their body temperature. After topical anesthesia with application of 
oxybuprocaine (4mg/mL, Anestocil, Edol) and pupillary dilation with topical application of 
tropicamide (10 mg/mL, Tropicil Top, Edol), the anterior chamber of the one eye was 
cannulated with a 30-gauge needle connected to reservoir infusing sterile saline solution 
(Figure 10A). The other eye was the contralateral control eye. The IOP was raised by 
elevating the reservoir to a height of 1.8 m. Retinal ischemia was confirmed by whitening 
of the iris and loss of the red reflex (Figure 10B). IOP was also measured with the Tonolab 
and it was increased to 80±1 mmHg. In order to avoid corneal opacity, viscoelastic 
solution (2% Methocel, Dávi II – Farmacêutica S.A.) was applied to both eyes. After 60 min 
of ischemia the needle was withdrawn and reperfusion was established. Fusidic acid 
ointment (10 mg/g, Fucithalmic, Leo Pharmaceutical) was applied in the end of the 
experiment. Animals were sacrificed 8h, 24h or 7 days after ischemia.  
 
 
 
Figure 9 - Experimental procedure for measurement of IOP. 
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2.4. Quantification of caffeine levels 
At the end of the treatment with caffeine, caffeine concentration was quantified in the 
serum, liver and brain by high performance liquid chromatography (HPLC) using a 
reverse-phase column [LiChro-CART 125 x 4 mm LiChrospher 100 RP-18 (5 µm) cartridge 
fitted into a ManuCART holder (Merck, Darmstadt, Germany)] and a Gilson system 
equipped with a UV detector set at 274 nm, as previously described (Duarte et al., 2012). 
Serum samples were obtained after centrifugation of blood at 2000 g, for 15 min. For the 
quantification in the liver and brain, 10 mg of tissue were homogenized with 100 µL Mili-
Q water, and frozen twice in liquid nitrogen. Then, 40% of the sample volume was added 
to 30% Perchloric Acid and mixed thoroughly, followed by centrifugation at 14000 rpm for 
10 min. The supernatant was collected and injected to the column.   
The eluent was KH2PO4 (115 mM) and acetonitrile (89/11, v/v %) at pH 3.10 with the 
flow rate of 1 mL/min. Chromatograms were recorded at 274 nm with a run time of 12 
min. The identification of caffeine was achieved by comparing the peak areas of standard 
samples, and the concentration of caffeine was calculated by converting the peak areas to 
concentration values with known standards ranging from 2 to 50 µM. 
 
2.5. Preparation of frozen retinal sections 
Animals were deeply anesthetized with an intraperitoneal injection of a solution of 
ketamine (90 mg/kg; Imalgene 1000) and xylazine (10 mg/kg; Ronpum 2%) and then 
transcardially perfused with phosphate-buffered saline (PBS, in mM: 137 NaCl, 2.7 KCl, 10 
Figure 10 - Retinal ischemia-reperfusion injury. A) Anterior chamber of the eye cannulated with a 30-
gauge needle. B) Visual effects of the ischemia in the eyes: whitening of the iris and loss of the red reflex 
(adapted from Sun et al., 2010). . 
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Na2HPO4, 1.8 KH2PO4; pH 7.4) followed by 4% (w/v) paraformaldehyde (PFA). The eyes 
were enucleated and post-fixed in 4% PFA for 1 hour. Then, the cornea and the lens were 
carefully dissected out and the eyecup was fixed for an additional 1 hour in 4% PFA. After 
washing in PBS, the tissue was cryopreserved in 15% sucrose in PBS for 1 hour followed 
by 30% sucrose in PBS for 1 hour. The eyecups were embedded in tissue-freezing medium 
(Optimal Cutting Temperature, OCT; Shandon Cryomatrix, Thermo Scientific) with 30% of 
sucrose in PBS (1:1), and stored at -80 C.  
The tissue was sectioned on a cryostat (Leica CM3050 S) into 10 µm thickness sections 
and mounted on Superfrost Plus glass slides (Menzel-Glaser, Thermo Scientific). Glass 
slides were dried overnight and then stored at -20 C.  
 
2.6. Immunohistochemistry 
The glass slides were defrosted at room temperature overnight. The sections were 
fixed with ice-cold acetone at -20 C for 10 min, and then rehydrated in PBS twice until 
OCT was removed. The tissue was surrounded with a hydrophobic pen and it was 
permeabilized with 0.25% Triton X-100 in PBS for 30 min. The sections were blocked in 
10% Normal Goat Serum plus 1% BSA in PBS for 30 min at room temperature in a 
humidified environment. After washing with PBS, the sections were incubated overnight 
with primary antibody (Table 1) prepared in 1% BSA in PBS at 4 C, in a humidified 
environment. Then, the sections were rinsed in PBS followed by incubation with the 
corresponding secondary antibodies (Table 1) prepared in 1% BSA in PBS for 1 hour at 
room temperature, in the dark. The sections were washed with PBS and then incubated 
with the nuclear dye 4',6-diamidino-2-phenylindole (DAPI), diluted 1:2000. The tissue was 
washed in PBS and mounted with fluorescent mounting medium (Dako, USA).   
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2.7. Assessment of reactive oxygen species  
ROS were detected using dihydroethidium (DHE), a probe that in the presence of 
superoxide anion (O2-) is oxidized to ethidium and intercalates with DNA emitting red 
fluorescence that can be observed with a microscope. The detection of ROS was 
performed as described previously (Sena et al., 2012), with some modifications as follows. 
Animals were deeply anesthetized with an intraperitoneal injection of a solution of 
ketamine (90 mg/kg; Imalgene 1000) and xylazine (10 mg/kg; Ronpum 2%) and then 
transcardially perfused with sterile saline (0.9% NaCl). The eyes were enucleated and 
were embedded in OCT with 30% of sucrose in PBS (1:1) and stored at -80 C. The glass 
slides were defrosted at room temperature overnight. The sections were rehydrated in 
PBS twice until OCT was removed. The tissue was surrounded with a hydrophobic pen and 
it was incubated with 2 μM DHE for 30 min at 37 C in the dark. After washing with PBS, 
the sections were fixed with 4% PFA (10 min). Then, the sections were washed with PBS 
and then incubated DAPI (1:2000). Sections were washed in PBS and mounted with 
fluorescent mounting medium (Dako, USA).  
 
Table 1 - List of primary and secondary antibodies used in immunohistochemistry. 
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2.8. Assessment of retinal thickness 
After defrosting the slides at room temperature overnight, the sections were 
rehydrated in PBS twice (5 min). Then the sections were incubated with hematoxylin 
solution for 3 min, followed by a superficial wash (3 seconds) with HCl 0.1% solution. The 
sections were washed in running tap water for 5 min, and then incubated with 0.5% eosin 
in 100% ethanol for 3 min. The sections were then washed in running tap water for 30 
seconds and then dehydrated in ascending alcohol solutions (95% and 100%, 1 min each). 
Then, sections were cleared through 2 changes of xylene (5 min). Finally, tissue sections 
were mounted with DPX mounting medium (FLUKA).  
 
2.9. Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end 
labeling (TUNEL) assay 
Cell death was detected with a TUNEL assay kit with fluorescein detection following 
the instructions provided by the manufacture (Promega). Briefly, sections were washed 
twice in PBS and then permeabilized with proteinase K (20 µg/ml) for 10 min. After 
washing twice in PBS, the sections were incubated with equilibration buffer (200 mM 
potassium cacodylate, 25 mM Tris-HCl, 0.2 mM DTT, 0.25 mg/mL BSA and 2.5 mM cobalt 
chloride) for 10 min. Then, sections were incubated with the recombinant TdT enzyme 
and with nucleotide mix containing dUTP conjugated to fluorescein at 37 C for 1 hour. 
The reaction was stopped by immersing the slides in saline-citrate (SSC) buffer (175 g/L 
NaCl, 88.1 g/L sodium citrate) for 15 min at room temperature. Then, the samples were 
washed three times in PBS 5 min, followed by incubation with the nuclear dye DAPI 
(diluted 1:2000). Sections were washed in PBS and mounted with fluorescent mounting 
medium (Dako, USA).  
 
2.10. Image analysis 
The samples were examined in a Zeiss LSM 710 confocal on an Axio Observer Z1 
microscope using an EC Plan-Neofluar 40x/1.30 Oil DIC M27 objective. Images 
(1024x1024 format) were collected using 405, 488 and 561 nm laser lines for excitation. 
Z-stacks images were acquired and merged using the maximum intensity projection mode 
of the Zeiss software (Zen 2009, Zeiss).  
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For the analysis of microglial reactivity, 4 images per section were acquired (4 sections 
each eye). In each picture, the number of cells immunoreactive to both Iba1 (Ionized 
calcium binding adaptor molecule 1) and OX-6 (Iba1+ OX-6+) was counted and it was 
expressed in percentage of the total number of cells immunoreactive to Iba1 (Iba1+).  
The analysis of IL-6 immunoreactivity and DHE staining was performed in the 
maximum projection images. For each eye, 6 pictures were acquired per section (4 
sections). Images were converted to 8-bit pictures and densitometric analysis was 
performed using the public domain ImageJ program (http://rsb.info.nih.gov/ij/) by 
quantifying the mean grey value. 
The survival of RGC was assessed by counting the number of cells immunoreactive to 
Brn3a (Brn3a+) in a Leica DM IRE2 fluorescence microscope using the 40x/0.70 HC PL APO 
CS objective. For each eye, 4 sections were analyzed and the number of cells Brn3a+ was 
counted in the entire retinal section and normalized to the length of the same section. 
Representative images were acquired with a Zeiss LSM 710 confocal microscope, as 
described previously. 
The retinal thickness was assessed by hematoxylin and eosin staining visualized in light 
microscope (Leica DM 4000 B). The average thickness (in µm) of the total retina was 
measured for each eye, in a total of 4 sections. Measurements, 16 per section, were 
obtained along the entire retinal section. 
The cell death was assessed by counting the number of TUNEL+ cells in a Leica DM IRE2 
fluorescence microscope using the 40x/0.70 HC PL APO CS objective. For each eye, 4 
sections were analyzed and the number of TUNEL+ cells was counted in the entire retinal 
section and normalized to the length of the same section. Representative images were 
acquired with a Zeiss LSM 710 confocal microscope, as described previously. 
 
2.11. Quantification of pro-inflammatory cytokines  
The concentration of pro-inflammatory cytokines tumor necrosis factor (TNF), IL-1β 
and IL-6 in the retina was quantified by Enzyme-linked immunosorbent assay (ELISA) 
following the instructions provided by the manufacturer (Peprotech, UK). The animals 
were sacrificed, the eyes enucleated and the retinas dissected in ice-cold PBS. The retinas 
were then homogenized in lysis buffer (20 mM imidazole HCl, 100 mM KCl, 1 mM MgCl2, 
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1% Triton X-100, 1 mM EGTA,1 mM EDTA, 10 mM NaF, 1 mM Na3VO4; pH 7.4) 
supplemented with protease inhibitor (Complete mini, Roche). The tissue was centrifuged 
at 10.000 g for 5 min at 4 C, the supernatant was collected and a small aliquot was saved 
for protein concentration using the BCA Protein assay kit (Pierce, Thermo Scientific). The 
samples were diluted three times with diluent solution (0.05 % Tween-20, 0.1 % BSA in 
PBS) and stored at -80 C until used. The absorbance at 405 nm, with wavelength 
correction at 650 nm, was measured with a multimode microplate reader (Synergy HT, 
Biotek, USA). The concentrations of TNF, IL-1β and IL-6 in retinal samples were 
determined by extrapolation of the standard curve using recombinant cytokines provided 
by manufacturer and reported as pictograms per milligram protein (pg/mg protein). To 
normalize the data, a ratio of the pro-inflammatory cytokine levels in the I-R-injured 
retina to the contralateral eye was calculated and used for statistical analysis. 
 
2.12. Statistical analysis 
Data that were outside the range mean ± 2 SD were excluded. Results are presented as 
mean ± SEM for the number of eyes indicated in parentheses above each bar in the 
graphs. Statistical analysis was performed in Graph Pad Prism 5 software using two-tailed 
unpaired Student’s t-test, and p<0.05 was considered to represent a significant 
difference. 
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3. Results 
In this work, we aimed to investigate whether the modulation of A2AR controls the 
inflammatory response in the retina in a model of I-R injury. In addition, the potential 
protective effect of A2AR modulation was investigated. Therefore, A2AR agonists or 
antagonists were injected intravitreally 2h before ischemia, or caffeine, a non-selective 
antagonist of A1R and A2AR, was administered orally in the drinking water two weeks 
before ischemia and until the end of the experiment. 
 
3.1. Role of A2AR modulation on retinal I-R injury 
 
3.1.1. Levels of pro-inflammatory cytokines 
In acute and transient retinal ischemia, potentially toxic mediators are released by 
activated inflammatory cells, by glial elements, and by injured neurons (Sanchez et al., 
2003; Gesslein et al., 2010). In order to investigate the modulatory role of A2AR in retinal 
I-R injury, selective A2AR antagonist or agonist were injected intravitreally before the 
injury, and the levels of pro-inflammatory cytokines TNF, IL-1β, and IL-6  were assessed 8h 
(Figure 11) and 24h (Figure 12) post-ischemia by ELISA.  
The levels of TNF, after 8h of reperfusion, in I-R retinas treated with saline were 
307.5±103.1 pg/mg prot, which corresponds to a ratio of 1.3±0.3 (Figure 11A). The ratio 
of TNF levels in the retinas treated with CGS 21680 or SCH 58261 was not significantly 
different from saline-treated retinas (1.8±0.7 and 1.9±1.1 fold change, respectively).  
After 8h of reperfusion, in I-R retinas treated with saline, the levels of IL-1β were 
3.2±0.4 fold-increased (Figure 11B) compared to the contralateral retinas (399.2±77.2 
pg/mg prot vs 1167.2±191.2 pg/mg prot). The injection of CGS 21680 in the vitreous did 
not significantly change IL-1β levels ratio of I-R retinas to contralateral retinas 
(424.9±152.2 pg/mg prot in contralateral retinas vs 570.6±131.0 pg/mg prot in I-R 
retinas), which corresponds to 1.8±0.7 fold-change. Intravitreal injection of SCH 58261 
significantly increased IL-1β ratio by 7.0±2.8 fold (332.3±138.3 pg/mg prot in contralateral 
retina vs 1564.7±639.5 pg/mg prot in I-R retinas), as compared to the saline-treated 
retinas.  
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The levels of IL-6 in the saline-treated retinas contralateral to the injury were 
3754.8±1132.9 pg/mg prot, and in I-R retinas were 6691.3±3568.0 pg/mg prot, resulting 
in a ratio of 1.7±0.7 (Figure 11C). Intravitreal injection of CGS 21680 did not significantly 
change the IL-6 levels ratio (1.3±0.1 fold-change) as compared to saline-treated retinas. In 
addition, intravitreal administration of SCH 58261 did not significantly change IL-6 levels 
ratio (1.9±1.0 fold-change), as compared to saline-treated retinas.  
 After 24h of reperfusion, the levels of TNF after I-R injury in saline-treated animals 
were 547.1±64.2 pg/mg prot in the contralateral retinas and 620.1±149.9 pg/mg prot in I-
R retinas, which corresponds to 1.2±0.3 fold change (Figure 12A). The intravitreal 
injection of CGS 21680 and SCH 58261 results in 1.9±0.5 and 1.6±0.3 fold change in I-R 
retinas, respectively. 
IL-1β levels in the saline-treated retinas contralateral to the injury were 334.7±159.7 
pg/mg prot vs 653.9±182.1 pg/mg prot in I-R retinas, resulting in 2.5±0.5 fold increase 
(Figure 12B). In the retinas with intravitreal injection of CGS 21680, the concentration of 
IL-1β were 845.4±272.0 pg/mg prot and 1029.3±403.8 pg/mg prot, for contralateral and I-
R retinas, respectively, corresponding to 2.0±0.7 fold-change. Intravitreal injection of SCH 
58261 did not significantly change the IL-1β concentration ratio (392.3±110.9 pg/mg prot 
and 523.0±177.1 pg/mg prot in contralateral and I-R retinas, respectively, resulting in 
1.6±0.4 fold change). 
The levels of IL-6 in the saline-treated retinas contralateral to the injury were 
2031.1±360.3 pg/mg prot, and in I-R retinas were 2687.7±932.0 pg/mg prot, resulting in a 
Figure 11 - Effect of CGS 21680 and SCH 58261 in retinal levels of TNF (A), IL-1β (B) and IL-6 (C) induced 
by I-R injury at 8 hours of reperfusion. Animals were injected in the vitreous with saline, CGS 21680 or 
SCH 58261 2 h before I-R, and the levels of TNF, IL-1β and IL-6 levels were quantified by ELISA. Both 
contralateral and I-R eyes were injected. The results represent the mean ± SEM for the number of eyes 
indicated in parentheses above each bar, and are expressed as the ratio of I-R eye to contralateral eye. 
*p<0.05, compared with saline, Student’s t-test. 
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ratio of 1.4±0.4 (Figure 12C). Intravitreal injection of CGS 21680 and SCH 58261 results in 
1.2±0.2 or 1.9±0.5 fold-change in I-R retinas, respectively. 
 
 
3.1.2. Microglial reactivity  
Microglia reactivity was assessed by immunohistochemistry using antibodies that 
recognize the Iba1 which is a microglia/macrophage-specific calcium-binding protein, and 
can be used as a marker of microglia/macrophages (Ito et al., 2001). OX-6 is an antibody 
recognizing the major histocompatibility complex (MHC) class II antigen which is only 
expressed by activated microglia/macrophage (Zhang et al., 2005; Kettenmann et al., 
2011). Therefore, microglia reactivity was assessed by immunohistochemistry with 
antibodies against Iba1 (total number of microglia/macrophages) and OX-6 (active 
microglia/macrophages). The number of cells immunoreactive to both OX-6 and Iba1 was 
expressed as a percentage of total microglia/macrophages.  
Retinal sections reveal the positioning of cells Iba1+ at the level of internal layers of 
retina (INL, IPL and GCL). Microglial cells were more ramified (resting) in the saline-
treated contralateral retinas than in saline-treated I-R retinas (Figure 13A).  
In saline-treated contralateral retinas, most of Iba1+ cells were not immunoreactive to 
OX-6 (10.6±8.9 % of total; Figure 13B).  
 
 
 
Figure 12 - Effect of CGS 21680 and SCH 58261 in retinal levels of TNF (A), IL-1β (B) and IL-6 (C) induced 
by I-R injury at 24 hours of reperfusion. Animals were injected in the vitreous with saline, CGS 21680 or 
SCH 58261 2 h before I-R, and the levels of TNF, IL-1β and IL-6 levels were quantified by ELISA. Both 
contralateral and I-R eyes were injected. The results represent the mean ± SEM for the number of eyes 
indicated in parentheses above each bar, and are expressed as the ratio of I-R eye to contralateral eye. 
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Figure 13 - Effect of CGS 21680 and SCH 58261 in the reactivity of microglia after retinal I-R injury. 
Animals were injected in the vitreous with saline, CGS 21680 or SCH 58261 2 h before I-R, and were 
sacrificed 24h post I-R injury. Retinal sections were stained with antibodies against Iba1 (green) and OX-
6 (red). Nuclei were stained with DAPI (blue). Representative images are depicted in A. B: Activated 
microglia/macrophages (OX-6- Iba1-immunoreactive cells) were expressed as the ratio OX-
6+Iba1+/Iba1+, and were presented as the percentage of total microglia/macrophages (Iba1-
immunoreactive cells). The results represent the mean ± SEM for the number of eyes indicated in 
parentheses above each bar. From each eye, four retinal sections were analyzed, and from each section 
six images were randomly acquired. *p<0.05, compared with contralateral eye; #p<0.05, compared with 
saline-treated I-R retinas, Student’s t-test. ONL: outer nuclear layer; OPL: outer plexiform layer; INL: 
inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer. Scale bar = 20 µm (detail images) 
or 50 µm. 
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Retinal I-R injury significantly increased the percentage of OX-6-positive cells (48.9±7.8 
% of total, n=3, p<0.05). In CGS 21680-treated I-R retinas the percentage of OX-6+ cells 
induced by I-R injury significantly increased (31.3±7.8% of total, n=4, p<0.05) when 
compared with contralateral eye. In SCH 58261-treated I-R retinas the percentage of OX-
6+ cells (8.9±8.2%, n=4) was not significantly different from the contralateral eye, but 
when compared with saline-treated I-R retinas there is a significantly decrease of OX-6+ 
cells (p<0.05). These results indicate that blockade of A2AR may attenuate microglial 
reactivity.   
 
3.2. Effect of caffeine on retinal I-R injury model 
3.2.1. Characteristics of animals involved in the study  
Caffeine (1 g/L) was administered in the drinking water during 2 weeks prior I-R and 
until the end of the experiment (24h or 7 days of reperfusion). The animals were housed 
two per cage. Weight and fluid intake were registered in some animals during the 
treatment which allowed us to estimate the daily caffeine consumption per animal (Table 
2).  
Table 2 - Characteristics of animals involved in the study. 
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Fluid intake was not statistically different throughout the study, and between the two 
groups of animals.  
Caffeine concentration was quantified by HPLC (Figure 14), in the serum, liver and 
brain samples that were collected immediately after sacrificing the animals 24h and 7 
days after I-R injury.  
 
Some reports have demonstrated that caffeine consumption increases IOP in glaucoma 
patients (Avisar et al., 2002), while others assume that ingestion of caffeine did not have 
effect on IOP (Varma and Chandra, 2011). Therefore, IOP was measured regularly with a 
rebound tonometer. Treatment with caffeine did not significantly change IOP, as 
compared with animals drinking water (Table 2).  
 
3.2.2. Effect of caffeine on retinal I-R injury rat model: 24 h post I-R injury 
3.2.2.1. Microglia reactivity  
As already mentioned above, microglia reactivity was assessed by 
immunohistochemistry with antibodies against Iba1 (total number of 
microglia/macrophages) and OX-6 (active microglia/macrophages).  
Iba1+ cells located at the level of internal layers of retina (INL, IPL and GCL) were not 
changed by caffeine administration (Figure 15A).  
The number of cells immunoreactive to both OX-6 and Iba1 was expressed as a 
percentage of total microglia/macrophages (Figure 15B).  
Figure 14 - Representatives HPLC chromatograms of A) rat blank serum and B) rat serum spiked with 
caffeine. 
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In the animals drinking water, I-R injury increased the number of cells immunoreactive 
to OX-6 (12.3±5.7% of total, n=5), compared to the corresponding contralateral retinas 
(2.5±1.6% of total, n=5). In I-R retinas from caffeine-treated animals the number of cells 
immunoreactive to OX-6 significantly increased (18.2±6.2% of total, n=8, p<0.05), when 
compared with the contralateral retinas from caffeine-treated animals (0.6± 0.6% of total, 
n=8), indicating an increase in microglia reactivity. 
Moreover, no statistical differences were found between contralateral retinas from 
water-treated group and caffeine-treated group. 
Figure 15 - Caffeine increased the number of activated microglia induced by I-R injury at 24h of 
reperfusion. Caffeine was administered in the drinking water for 2 weeks prior injury and until the end 
of the experiment. Retinal sections were stained with antibodies against Iba1 (green) and OX-6 (red). 
Nuclei were stained with DAPI (blue). Representative images are depicted in A. B: Activated 
microglia/macrophages (OX-6- Iba1-immunoreactive cells) were expressed as the ratio OX-6
+
Iba1
+
/Iba1
+
, 
and were presented as the percentage of total microglia/macrophages (Iba1-immunoreactive cells). The 
results represent the mean ± SEM for the number of eyes indicated in parentheses above each bar. 
From each eye, four retinal sections were analyzed, and from each section six images were randomly 
acquired. *p<0.05, compared with contralateral eye, Student’s t-test. ONL: outer nuclear layer; OPL: 
outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer. Scale 
bar = 20 µm (detail images) or 50 µm. 
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3.2.2.2. Levels of pro-inflammatory cytokines 
Caffeine administration did not induce statistically significant changes in the ratio of 
TNF (Figure 16A), IL-1β (Figure 16B) and IL-6 (Figure 16C) compared to animals drinking 
water at 24 h of reperfusion.  
After 24h of reperfusion, the levels of TNF after I-R injury in water-treated animals 
were 450.4±137.2 pg/mg prot in the contralateral retinas and 568.7±137.2 pg/mg prot in 
I-R retinas, which corresponds to 1.3±0.2 fold change (Figure 16A). In caffeine-treated 
there was a 1.5±0.4 fold change of TNF levels in I-R retinas. 
After 24h of reperfusion the levels of IL-1β in the water-treated retinas contralateral to 
the injury were 532.1±161.4 pg/mg prot vs 1030.2±275.5 pg/mg prot, resulting in 2.0±0.4 
fold increase in I-R retinas (Figure 16B). Caffeine administration changed IL-1β 
concentration by 1.8±0.3 fold (943.3±351.74 pg/mg prot vs 1520.2±437.6 pg/mg prot). 
The levels of IL-6 in the water-treated retinas contralateral to the injury were 
438.0±79.2 pg/mg prot vs 561.3±258.0 pg/mg prot, resulting in 1.1±0.3 fold changed in I-
R retinas (Figure 16C). In caffeine-treated retinas there is an increase of IL-6 
concentration by 2.2±0.7 fold (1094.4±264.4 pg/mg prot vs 1779.3±489.5 pg/mg prot). 
 
 
 
 
 
 
Figure 16 - Caffeine did not change retinal levels of TNF (A), IL-1β (B) and IL-6 (C) induced by I-R injury at 
24h of reperfusion. Caffeine was administered in the drinking water for 2 weeks prior I-R injury and until 
the end of the experiment. TNF, IL-1β and IL-6 levels were quantified by ELISA. The results represent the 
mean ± SEM for the number of eyes indicated in parentheses above each bar, and are expressed as the 
ratio of I-R eye to contralateral eye. 
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3.2.2.3. Production of reactive oxygen species 
DHE imaging allows the assessment of superoxide formation, since in the presence of 
superoxide is oxidized and emits red fluorescence. DHE staining was observed in the 
entire retina (Figure 17A) and was quantified in the inner retinal layers (INL, IPL and GCL). 
No statistically differences were detected in DHE staining between the groups and 
between I-R and contralateral retinas (Figure 17B).  
 
3.2.2.4. Retinal thickness 
Retinal thickness was assessed after staining retinal sections with hematoxylin and 
eosin (Figure 18A). Hematoxylin has a deep blue-purple color and stains nucleic acids and 
eosin is pink and stains proteins nonspecifically (Fischer et al., 2008).  
Overall, no major changes were found concerning the thickness of the retina between 
the five experimental conditions (Figure 18B). 
Figure 17 - Effect of caffeine on the production of reactive oxygen species induced by I-R injury at 24h of 
reperfusion. Caffeine was administered in the drinking water for 2 weeks prior I-R injury and until the 
end of the experiment. Reactive oxygen species were assayed with DHE fluorescence. Representative 
images are depicted in A. B: The intensity of DHE staining was quantified using ImageJ software. The 
results represent the mean ± SEM for the number of eyes indicated in parentheses above each bar. 
From each eye, four sections were stained and from each section six images were randomly acquired. 
ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; 
GCL: ganglion cell layer. Scale bar = 50 µm. 
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3.2.2.5. Cell death 
In the present study we aimed to evaluate if caffeine could prevent I-R injury-induced 
cell death at 24 h of reperfusion. Cell death was assessed using the TUNEL assay (Figure 
19A).  
We observed that in water-treated retinas I-R injury significantly increased the number 
of TUNEL+ cells (15.4±6.8 cells/mm, n=4, p<0.05) comparing with contralateral retinas 
(1.2±0.6 cells/mm). Also, in caffeine-treated subjected to I-R injury retinas there was a 
significantly increase in the number of TUNEL+ cells (44.5±5.5 cells/mm, n=4, p<0.001) 
comparing with contralateral retinas (0.6±0.3 cells/mm). Moreover, caffeine significantly 
increased the number of TUNEL+ cells induced by I-R injury (p<0.05) compared to I-R 
retinas of animals drinking water. Caffeine administration in non-I-R retinas did not cause 
changes compared to the contralateral eyes (Figure 19B). 
Figure 18 - Effect of caffeine in retinal thickness 24h after I-R. Caffeine was administered in the drinking 
water for 2 weeks prior I-R and until the end of the experiment. Retinal sections were stained with 
hematoxylin (blue-purple color) and eosin (pink). Representative images are depicted in A. B: Retinal 
thickness was quantified using ImageJ software. The results represent the mean ± SEM for the number 
of eyes indicated in parentheses above each bar. From each eye, four sections were stained and from 
each section 16 measurements were made. RPE: retinal pigment epithelium; OS: outer segments; ONL: 
outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: 
ganglion cell layer. Scale bar = 50 µm. 
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3.2.2.6. RGC loss  
The loss of RGCs was assessed by immunohistochemistry with an antibody that 
recognizes the transcription factor Brn3a that in the retina is expressed only in RGCs and 
can be used to identify these cells (Figure 20A) (Nadal-Nicolas et al., 2009).  
As can be observed in Figure 20B, there is a tendency to decrease the number of 
Brn3a+  cells induced by I-R injury (16.4±1.5 cells/mm, n=4, p=0.0844) compared with 
contralateral retina (21.3±1.8 cells/mm). In caffeine-treated I-R retinas Brn3a+ cells were 
changed compared with contralateral retina (17.3±2.6 cells/mm vs 12.0±3.4 cells/mm) 
(Figure 20B). Moreover, caffeine did not affect the percentage of RGC survival. Caffeine 
per se did not induce Brn3a+ cells loss, as can be seen in caffeine-treated group non I-R 
retinas. 
Figure 19 - Caffeine administration increased cell death induced by I-R injury at 24 h of reperfusion. 
Caffeine was administered in the drinking water for 2 weeks prior injury and until the end of the 
experiment. Cell death was assayed with TUNEL assay. Nuclei were stained with DAPI (blue). 
Representative images are depicted in A. B: TUNEL
+ 
cells (green) were counted and were expressed per 
mm of retina.
 
The results represent the mean ± SEM for the number of eyes indicated in parentheses 
above each bar. From each eye, four retinal sections were analyzed, and from each section six images 
were randomly acquired. *p<0.05, ***p<0.0001, compared with contralateral eye, #p<0.05, compared 
with water-treated I-R retinas, Student’s t-test. ONL: outer nuclear layer; OPL: outer plexiform layer; INL: 
inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer. Scale bar = 50 µm. 
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3.2.3. Effect of caffeine on retinal I-R injury rat model: 7 d post I-R injury 
Next, we aimed to evaluate if, in a later stage of I-R injury, caffeine could be protective 
against ischemic damage. For this propose we evaluated damage caused 7 days after 
ischemia.  
 
3.2.3.1. Microglia reactivity 
As already mentioned, microglia reactivity was assessed by immunohistochemistry 
with antibodies against Iba1 (total number of microglia/macrophages) and OX-6 (active 
microglia/macrophages). The number of cells immunoreactive to both OX-6 and Iba1 was 
expressed as a percentage of total microglia/macrophages.  
Figure 20 - Effect of caffeine on RGC number after 24h post-injury. Caffeine was administered in the 
drinking water for 2 weeks prior injury and until the end of the experiment. Retinal sections were 
stained with an antibody against Brn3a (red). Nuclei were stained with DAPI (blue). Representative 
images are depicted in A. B: Brn3a-immunoreactive cells were counted and were expressed per mm of 
retina. C) Percentage of surviving RGCs is expressed as the ratio of I-R eye to contralateral eye. The 
results represent the mean ± SEM for the number of eyes indicated in parentheses above each bar. 
From each eye, four retinal sections were analyzed, and from each section six images were randomly 
acquired. ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner 
plexiform layer; GCL: ganglion cell layer. Scale bar = 50 µm. 
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In the water-treated group, I-R injury significantly increased the number of cells 
immunoreactive to OX-6 (22.2±1.3% of total, n=2, p<0.01), compared to the 
corresponding contralateral retinas (0.5±0.5% of total, n=2), indicating an increase in 
microglia reactivity (Figure 21B).  
 
In caffeine-treated I-R retinas the number of cells immunoreactive to OX-6 significantly 
increased (11.7±2.6% of total, n=6, p<0.01), when compared with the contralateral 
retinas from caffeine-treated animals (1.5±2.6% of total, n=6). Caffeine administration 
tend to decrease the number of cells immunoreactive to OX-6 induced by I-R injury 
(11.7±2.6% of total, n=6, p=0.0733) comparing with water-treated I-R retinas. 
Moreover, no statistical significant differences were found between contralateral 
retinas of the two groups. 
 
Figure 21 - Caffeine decreased the number of activated microglia induced by I-R injury at 7 days of 
reperfusion. Caffeine was administered in the drinking water for 2 weeks prior injury and until the end 
of the experiment. Retinal sections were stained with antibodies against Iba1 (green) and OX-6 (red). 
Nuclei were stained with DAPI (blue). Representative images are depicted in A. B: Activated 
microglia/macrophages (OX-6- Iba1-immunoreactive cells) were expressed as the ratio OX-6
+
Iba1
+
/Iba1
+
, 
and were presented as the percentage of total microglia/macrophages (Iba1-immunoreactive cells). The 
results represent the mean ± SEM for the number of eyes indicated in parentheses above each bar. 
From each eye, four retinal sections were analyzed, and from each section six images were randomly 
acquired. **p<0.01, compared with contralateral eye, Student’s t-test. ONL: outer nuclear layer; OPL: 
outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer. Scale 
bar = 20 µm (detail images) or 50 µm. 
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3.2.3.2. Levels of pro-inflammatory cytokines 
The levels of TNF in the retina of animals drinking water seven days after ischemia 
were 1074.5±386.8 pg/mg prot and 2059.7±626.1 pg/mg prot in contralateral and I-R 
retinas, respectively, which corresponds to 2.2±0.4 fold change (Figure 22A). The TNF 
levels ratio of I-R retinas to contralateral retinas of caffeine-treated animals significantly 
decreased (1.2±0.1 fold change, n=6, p<0.05), as compared to animals drinking water. 
 
After 7 days of reperfusion the levels of IL-1β (Figure 22B) in the water-treated retinas 
contralateral to the injury were 1612.4±537.1 pg/mg prot, resulting in 2.2±0.4 fold 
increase in I-R retinas. Caffeine administration increased IL-1β concentration by 0.8±0.1 
fold (3725.8±1491.1 pg/mg vs 2411.1±603.4 pg/mg). IL-1β levels increasing induced by I-R 
injury in caffeine-treated retinas tend to be lower than in water-treated retinas (0.8±0.1, 
n=7, p=0.0595). 
The levels of IL-6 in the water-treated retinas contralateral to the injury were 
2458.0±81.0 pg/mg, resulting in 1.2±0.1 fold increase in I-R retinas (Figure 22C). In 
caffeine-treated retinas there is an increase of IL-6 concentration by 1.3±0.03 fold 
(2557.7±135.1 pg/mg vs 3362.3±259.1 pg/mg). 
In addition, immunoreactivity of IL-6 in the retina was also assessed (Figure 23). As can 
be observed, IL-6 immunoreactivity was mainly found in the OPL, IPL, INL and GCL. The 
immunoreactivity in I-R retinas of animals drinking caffeine is increased compared to the 
contralateral eye. The treatment with caffeine may decrease IL-6 immunoreactivity of I-R 
retinas, compared with retinas that were submitted to I-R from animals drinking water. 
Figure 22 - Caffeine decreased the levels of TNF (A), IL-1β (B) and IL-6 (C) induced by I-R injury at 7 days 
of reperfusion. Caffeine was administered in the drinking water for 2 weeks prior injury and until the 
end of the experiment. TNF, IL-1β and IL-6 levels were quantified by ELISA. The results represent the 
mean ± SEM for the number of eyes indicated in parentheses above each bar, and are expressed as the 
ratio of I-R eye to contralateral eye. *p<0.05, compared to water-treated group, Student’s t-test. 
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3.2.3.3. Production of reactive oxygen species 
DHE staining was used to assess the production of ROS 7 days after I-R injury (Figure 
24). At 7 days of reperfusion, DHE staining significantly increased in I-R retinas from 
animals drinking water (n=3, p<0.05) compared with contralateral retina.  
In caffeine-treated I-R retinas DHE staining is significantly decreased when compared 
to I-R retinas from animals drinking water (n=3, p<0.05). 
 
 
 
 
 
 
Figure 23 - Caffeine decreased IL-6 immunoreactivity 7 days after I-R. Caffeine was administered in the 
drinking water for 2 weeks prior injury and until the end of the experiment. Retinal sections were 
stained with antibodies against IL-6 (green). Nuclei were stained with DAPI (blue). Representative 
images are depicted in A. B: The intensity of IL-6 staining was quantified using ImageJ software. The 
results represent the mean ± SEM for the number of eyes indicated in parentheses above each bar. 
From each eye, four sections were stained and from each section six images were acquired. ONL: outer 
nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: 
ganglion cell layer. Scale bar = 50 µm. 
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3.2.3.4. Retinal thickness 
After 7 days of reperfusion, retinal thickness significantly decreased in water-treated I-
R retinas (147.9±7.8 µm, n=2, p<0.05) comparing with contralateral retinas (Figure 25B). 
The treatment with caffeine did not affect the thickness of the retina for both 
contralateral and I-R conditions (234.1±8.1 µm and 181.8±17.3 µm, respectively). The 
treatment of caffeine in non-I-R retinas does not affect retinal thickness. 
 
 
 
 
Figure 24 - Caffeine administration decreased the production of reactive oxygen species induced by I-R 
injury at 7 days of reperfusion. Caffeine was administered in the drinking water for 2 weeks prior injury 
and until the end of the experiment. Reactive oxygen species was assayed with DHE fluorescence. 
Representative images are depicted in A. B: The intensity of DHE staining was quantified using ImageJ 
software. The results represent the mean ± SEM for the number of eyes indicated in parentheses above 
each bar. From each eye, four sections were stained and from each section six images were acquired. 
*p<0.05, compared with contralateral eye, #p<0.05, compared with water-treated I-R retinas, Student’s 
t-test. ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform 
layer; GCL: ganglion cell layer. Scale bar = 50 µm. 
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3.2.3.5. Cell death  
Cell death by apoptosis was assessed by TUNEL assay. We observed that I-R injury in 
water-treated retinas significantly increased the number of TUNEL+ cells (6.4±1.2 
cells/mm, n=3, p<0.01) comparing with contralateral retinas (0.5±0.2 cells/mm) (Figure 
26). In caffeine-treated I-R retinas there was an increase in the number of TUNEL+ cells 
(3.0±0.8 cells/mm, n=5, p<0.01) comparing with contralateral retinas (0.2±0.1 cells/mm), 
but it was significantly decreased compared to I-R retinas of animals drinking water 
(p<0.05). Caffeine per se did not cause cell death. 
 
 
 
 
Figure 25 - Caffeine attenuated the decrease of retinal thickness induced by I-R injury 7 days after 
ischemia. Caffeine was administered in the drinking water for 2 weeks prior injury and until the end of 
the experiment. Retinal sections were stained with hematoxylin (blue-purple color) and eosin (pink). 
Representative images are depicted in A. B: Retinal thickness was quantified using ImageJ software. The 
results represent the mean ± SEM for the number of eyes indicated in parentheses above each bar. 
From each eye, four sections were stained and from each section 16 measurements were made. 
*p<0.05, compared with contralateral eye, Student’s t-test. RPE: retinal pigment epithelium; OS: outer 
segments; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner 
plexiform layer; GCL: ganglion cell layer. Scale bar = 50 µm. 
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3.2.3.6. RGC loss 
I-R injury significantly decreased the number of Brn3a+ cells in water-treated I-R retinas 
(8.0±3.6 cells/mm, n=5, p<0.01), comparing with contralateral retinas (22.8±1.4 
cells/mm). In caffeine-treated I-R retinas the number of Brn3a+ cells decreased compared 
with contralateral retinas (16.3±2.1 vs 9.3±3.7 cells/mm) but are not statistically 
significant. However, caffeine increased the percentage of RGCs in 74.1±27.6 %, 
comparing with water-treated retinas in which only 34.9±15.7 % of RGCs survived after I-
R injury. Caffeine per se did not induce Brn3a+ cells loss (Figure 27B). 
 
 
 
Figure 26 - Caffeine administration decreased cell death induced by I-R injury at 7 days of reperfusion. 
Caffeine was administered in the drinking water for 2 weeks prior injury and until the end of the 
experiment. Cell death was assayed by TUNEL assay. Nuclei were stained with DAPI (blue). 
Representative images are depicted in A. B: TUNEL-positive cells (green) were counted and were 
expressed per mm of retina. The results represent the mean ± SEM for the number of eyes indicated in 
parentheses above each bar. From each eye, four retinal sections were analyzed, and from each section 
six images were randomly acquired. **p<0.01, compared with contralateral eye, #p<0.05, compared 
with water-treated I-R retinas, Student’s t-test. ONL: outer nuclear layer; OPL: outer plexiform layer; INL: 
inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer. Scale bar = 50 µm. 
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Figure 27 - Caffeine administration decreased RGC loss induced by I-R injury at 7 days of reperfusion. 
Caffeine was administered in the drinking water for 2 weeks prior injury and until the end of the 
experiment. Retinal sections were stained with antibodies against Brn3a (red). Nuclei were stained with 
DAPI (blue). Representative images are depicted in A. B: Brn3a-immunoreactive cells were counted and 
were expressed per mm of retina. The results represent the mean ± SEM for the number of eyes 
indicated in parentheses above each bar. From each eye, four retinal sections were analyzed, and from 
each section six images were randomly acquired. **p<0.01, compared with contralateral eye, Student’s 
t test. ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform 
layer; GCL: ganglion cell layer. Scale bar = 50 µm. 
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4. Discussion  
Glaucoma is one leading cause of blindness in the world and it is characterized by 
progressive degeneration and death of RGCs (Vohra et al., 2013). Elevated IOP and age 
are important risk factors for the progression of the disease. The treatments available are 
directed towards lowering IOP, but the patients continue to lose vision. Therefore, 
neuroprotection of RGCs is thought as an important therapy in addition to therapies 
aimed to decrease IOP.  
Retinal ischemia is closely associated with pathophysiology of many retinal diseases, 
like glaucoma. In fact, retinal ischemia followed by reperfusion triggers RGC loss (Dorfman 
et al., 2012), and damage in various retinal layers (Johnson and Tomarev, 2010), as well as 
microglia activation (Halder et al., 2013). In the initial phases of the disease, microglia has 
the role to initiate the repair mechanism. However, an exaggerated microglia reactivity 
may lead to chronic inflammation, perpetuating the loss of RGCs (Langmann, 2007; 
Karlstetter et al., 2010).  Increased microglia reactivity was observed in the retina of 
glaucoma patients and experimental animal models (Neufeld and Liu, 2003; Bosco et al., 
2011).  
Activation of retinal microglial cell through preconditioning with LPS prevented cell 
damage in retina caused by I-R injury (Halder et al., 2013). Moreover, preconditioning 
with 5 min of ischemia followed 24h or 72 h later by 60 min also protected retina against 
the effects of ischemia (Ghiardi et al., 1999). These studies demonstrated that 
preconditioning initiated a compensatory or adaptive response to excitotoxic insults by 
microglia. 
Moreover, adenosine concentration have large changes after I-R injury which could be 
injurious to retina, but small adenosine concentration changes may induced a tolerant 
state ischemic injury (Ghiardi et al., 1999).  
Microglia are thought to be the principal source of pro-inflammatory mediators, such 
IL-1β, TNF, and nitric oxide (NO), which are elevated in the retina after I-R injury (Lee, 
2013). Increased production of cytokines and ROS contribute to the perpetuation of the 
neurodegenerative process (Sanchez et al., 2003; Ozerol et al., 2009; Gesslein et al., 
2010).  
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In I-R model there is a possibility to control the magnitude and the duration time of the 
elevation of the IOP. Both the duration of ischemia and reperfusion periods influence the 
proportion of RGC death. An ischemic period between 45 and 60 minutes induces 
significant RGCs loss, without inducing irreversible damage, and the reperfusion period 
also influences the proportion of RGCs loss. Cell death begins as soon as 3 to 24 h and 
after 5 days of reperfusion, a high percentage of cell loss is presently observed (Selles-
Navarro et al., 1996). For an ischemic time of 60 minutes, we found that I-R injury 
induced retinal cell death (assessed with TUNEL assay), loss of RGCs (counting the number 
of cells immunoreactive to Brn3a), and retinal thinning, which is in agreement with 
previous reports (Dorfman et al., 2012; Halder et al., 2013). 
In the retina, microglial cells are predominantly located in IPL but can be also observed 
in the GCL (Zhang et al., 2005), in accordance with our results. In addition, intravitreally 
injection of saline or A2AR agonist or antagonist did not change microglia localization.  
In this work, the contralateral eye was considered the control condition, since all eyes 
were injected with the drugs (also in saline-injected animals). In contralateral eyes (saline-
injected or animals drinking water) we did not observe substantial microglia reactivity 
(cells immunoreactive to OX-6). Interestingly, more OX-6+ cells were observed in eyes 
injected with saline than in animals drinking caffeine. One possible explanation could be 
the fact that intravitreal injection, even if of saline, can somehow induce changes in the 
retinal environment and induce microglia reactivity. Recently, it was reported ocular 
hypertension induces upregulation of GFAP and OX-6 and microglia reactivity in the 
contralateral retinas (Gallego et al., 2012). Although the experimental models are 
different, we should be aware that the contralateral eye may not be the best control, and 
naïve retinas should have been used also. 
Several studies reported that blockade of A2AR prevents injury in a number of brain 
conditions (Cunha, 2005; Cunha et al., 2008; Rebola et al., 2011). Moreover, blockade of 
A2AR can control neuroinflammation and also the recruitment of microglia (Orr et al., 
2009; Simoes et al., 2012). In the retina, microglia cells express A2AR (Liou et al., 2008), 
therefore we hypothesize that A2AR modulation could control retinal neuroinflammation. 
However, in general, neither the activation nor the blocking of A2AR altered the levels of 
pro-inflammatory cytokines, except for 8h reperfusion in which SCH 58261 increased IL-
1β.  
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Microglia cells became reactive early after I-R injury. In fact, OX-6 (MHC II antigen 
presenting cells) was reported not to be expressed 6 hours after ischemia, but after 1, 3 
and 7 days (Zhang et al., 2005). Intravitreal administration of SCH 58261 decreased the 
number of cells expressing OX-6 (microglia/machrophages), suggesting that A2AR 
blockade can, in a certain level, decrease microglia reactivity.  
Previously it was reported that activation of A2AR attenuated retinal thinning 
induced by I-R injury (Konno et al., 2006), suggesting that A2AR activation prevents retinal 
cell death. In this work, A2AR agonists, 2-(6-cyano-1-hexyn-1-yl)adenosine (2-CN-Ado) 
and CGS 21680, were administered systemically (30 min before ischemia), intravenously 
and intraperitoneally, respectively, or topically (2-CN-Ado). Although we did not assess 
retinal thickness in these experiments, we can speculate that we would not observe 
prevention in retinal thickness with either CGS 21680 or SCH 58261. The different routes 
of administration and the time frame of drug administration may help explaining the 
potential contradictory results. A2AR is known to have bidirectional effects, depending on 
the route of administration (Dai and Zhou, 2011). For instance, peripheral administration 
of A2AR agonist protected the hippocampus against kainate-induced excitotoxicity, but 
intrahippocampal administration did not protect the region to any degree (Jones et al., 
1998).  
 It is important to note that the source of these cytokines was not determined. In the 
present study, reactive astrocytes also secrete many of the same cytokines. As a 
consequence of I-R injury, astrocytes become activated, proliferate, produces pro-
inflammatory cytokines, chemokines and ROS (Uno et al., 1997; Tezel and Wax, 2000; 
Reinehr et al., 2007). Astrocyte activation initiates both protective and neurotoxic 
pathways, and is increasingly associated with worsened outcomes in the injured CNS 
(Faulkner et al., 2004; Abramov and Duchen, 2005; Fernandez et al., 2007; Toft-Hansen et 
al., 2011). Neurons also contribute to the inflammatory process and blockade of A2AR 
also control the deleterious effects of IL-1β on neuronal viability (Rebola et al., 2011). 
Since we did not detect changes in the expression of pro-inflammatory cytokines after I-R 
injury, even after SCH 58261 administration causing decreased microglia reactivity, we 
have to consider that other cells in retina are contributing to inflammation. 
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Caffeine is the most commonly used psychostimulant in the world and its effects are 
partly mediated by antagonizing adenosine receptors (Cognato et al., 2010).  
In humans, a single cup of coffee provides a peak plasma caffeine concentration of 1-
10 µM (Fredholm et al., 1999). In rats, we found that serum caffeine concentration was 
55 µM (2 weeks consumption) and 98 µM (3 weeks consumption), which is similar with 
other studies (Duarte et al., 2009; Duarte et al., 2012). It demonstrates that the caffeine 
dose selected (1 g/L) represents a high intake of caffeine, corresponding to 5-8 cups of 
coffee per day in humans.  
Caffeine consumption may influence IOP (Avisar et al., 2002). The mechanism of 
how caffeine contributes to this increased in IOP is not fully understood. By inhibiting 
phosphodiesterase, caffeine leads to an increase in cAMP, and increased intraocular 
levels of cAMP leads to a hypotensive effect (Kurata et al., 1998). Moreover,  caffeine 
intake increases blood pressure (Nurminen et al., 1999) which may influences aqueous 
humor outflow (Xu et al., 2007). Taking this into account, IOP was measured regularly 
during caffeine administration period and we found that its ingestion did not change IOP 
in rats.  
Caffeine is a non-selective antagonist of A1R and A2AR. These receptors have similar 
affinity for caffeine, slightly higher for A2AR in brain preparations (Costenla et al., 2010; 
Orru et al., 2013). Previous reports suggest that chronic daily caffeine administration 
protects against brain injury in different animal models of neurodegenerative diseases, 
such as Parkinson’s and Alzheimer’s diseases, ischemic and traumatic brain injury, and 
allergic encephalitis (Phillis, 1995; Chen et al., 2001; Popoli et al., 2002; Arendash et al., 
2006; Deleu et al., 2006; Riksen et al., 2006; Li et al., 2008; Sonsalla et al., 2012). Caffeine 
administration also prevents memory impairment triggered by a convulsive episode in 
early life and in streptozotocin diabetic rats (Duarte et al., 2009; Cognato et al., 2010). 
More recently, also in an animal model of Machado-Joseph disease caffeine delayed 
striatal pathology (Goncalves et al., 2013). Regarding these effects, we aimed to evaluate 
whether long-term caffeine intake prevents retinal neuroinflammation and cell death 
induced by retinal I-R injury. 
Evidence exists regarding the effect of caffeine in controlling neuroinflammation. Using 
the murine BV2 microglial cell line, it was shown that caffeine suppressed the LPS-
induced pro-inflammatory mediators NO, prostaglandin E2 and TNF by inhibiting Akt-
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dependent NF-κB activation and the ERK signaling pathway (Kang et al., 2012). Moreover, 
caffeine administration was reported to reduce LPS- and age-induced microglia activation 
in the rat hippocampus (Brothers et al., 2010a). 
In an animal model of Parkinson’s disease caffeine was found to reduce the levels of 
NO, microglial activation and thereby protect dopaminergic neurodegeneration (Yadav et 
al., 2012). 
We analyzed the effect of caffeine at 24h and 7 days post-ischemia. We found that 
caffeine exacerbated microglia reactivity at 24 h after ischemia, without significant 
changes in the levels of cytokines. However, when we analyzed the effect of caffeine 7 
days after ischemia we found that caffeine prevented the increase in microglia reactivity 
and decreased the levels of pro-inflammatory cytokines. The effects of caffeine regarding 
neuroprotection were mainly due to the prevention of cell death and retinal thickness. 
One possible explanation for the apparent contradictory results could be the fact that 
immediately after injury microglia cells become activated to initiate the repair 
mechanisms. Caffeine may “prime” microglia to respond to injury more effectively, 
culminating in less cell death and an increase in RGC survival, as observed 7 days after 
ischemia. 
Microglia neuroinflammation is commonly associated with the production of ROS, 
which are proposed to be involved in RGC death. Production of ROS targets innumerous 
retinal functions. It was reported that there is an overproduction of ROS after ischemia 
which mainly occurs during tissue reoxygenation in the reperfusion period (Kuriyama et 
al., 2001). Controlling the production of ROS, RGC rescue is improved (Yokota et al., 2011; 
Liu et al., 2012). Our results corroborate these findings demonstrating that caffeine 
decreases the production of ROS. Caffeine was demonstrated to have properties of 
scavenging various ROS, namely superoxide and hydroxyl radical (Shi et al., 1991; 
Devasagayam et al., 1996). Caffeine was also found to be physiologically effective in 
protecting the lens against ROS-induced damage caused by incubating the lens exposed 
to UV in kynurenine-containing medium (Varma and Hegde, 2010). The levels of GSH and 
ATP in the lens were maintained better in the presence of caffeine than in its absence. 
The exact molecular mechanism and what cells are contributing to this inflammatory 
response remains unknown. In line with what has been said so far at 24h after ischemia, 
the inflammation and microglial reactivity induced by I-R injury are increased in result of 
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caffeine administration, and in later stages post-injury this procedures is controlled. As 
cell death can be the result of inflammatory process the exaggerated microglial activation 
and inflammation leads to large increase of cell death. It seems that caffeine by 
controlling inflammatory process induced by I-R injury, decrease cell death in retina.  
Retinal thinning may be explained by loss of cells and synapse arborization. Retinas in 
average are 170 µm thick (Dorfman et al., 2012). The most affected layer by I-R injury is 
IPL, as its thickness start to decrease after 72 h of a 60 min period ischemia (Liu et al., 
2012). We did not detect changes in the thickness of the retina after 24h of ischemia, 
which is in agreement with the lack of statistical significance in the number of RGCs 
present. 
One important aspect to consider is that the markers used to identify microglia are 
also present in macrophages. As there is no known cell-surface marker to distinguish CNS-
resident from blood-borne macrophages, it is difficult to discern the resident microglia 
from monocytes that enter the CNS from the bloodstream and subsequently adopt 
microglial-cell morphology (Flugel et al., 2001). The neuroinflammatory response, either 
resident microglia or infiltrating monocytes, becomes a critical issue in determining, not 
only the nature of the response and characteristics of the injury, but also the 
effectiveness of modulating their response. In our model, it is established that the BBB is 
compromised (Tong et al., 2013), leading to leakage to the retinal parenchyma, 
suggesting that monocytes infiltrate contributing to the inflammatory response. 
Nevertheless, it was reported that caffeine protects against high cholesterol diet-induced 
disruption of the BBB (Chen et al., 2008), suggesting that it may also influence the 
permeability of the BRB. 
In conclusion, intravitreal administration of A2AR agonist or antagonist does not seem 
to modulate the pro-inflammatory response in the retina induced by I-R injury. 
Nevertheless, long-term caffeine administration prior I-R may attenuate retinal 
neuroinflammation and prevent cell death, namely of RGCs. 
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5. Conclusions and Future directions 
The results presented in this thesis allowed us to conclude that: 
 Retinal I-R injury increased microglia reactivity, which was prevented by A2AR 
antagonist; 
 The A2AR agonist or antagonist did not change the levels of pro-inflammatory 
cytokines in the retina after I-R injury; 
 Caffeine induced a high inflammatory response 24 h post-injury, exacerbating the 
effect of I-R; 
 Caffeine decreased the number of  reactive microglia, pro-inflammatory cytokines 
and the production of ROS at 7 days post-injury; 
 Caffeine prevented the increase in cell death and retinal thinning induced by I-R 
injury. 
 
Further research should be performed to investigate the effects of systemic 
administration of A2AR agonist and antagonist. For this, we aim to evaluate the effect of 
CGS 21680 and SCH 58261 injected intraperitoneally in the I-R injury model.  
Considering previous data on the effect of caffeine in the hemato-retinal barrier, we 
intend to assess its influence on the I-R injury model.  
Moreover, in order to complete these results the study may be conducted in a 
glaucoma model. 
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